Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
5
Bullish
3
Bearish
6
Neutral
5
Bullish
35
Bearish
0
Neutral
0
Bullish
32
Gland Pharma is an India‑based vertically integrated manufacturer of sterile injectable formulations and a growing CDMO provider, operating multiple finished dosage and API facilities in India and the recently acquired Cenexi network in Europe that together supply the U.S., Europe, Canada, Australia and rest‑of‑world markets.
Q1 FY27 highlighted a strong start with consolidated revenue of INR18,003 million (up 20% YoY), CDMO now contributing 50% of revenue, strong U.S. growth of 32% and reported EBITDA margin of 27% (adjusted 28% excluding ESOP), signalling improving profitability driven by higher CDMO mix and operating leverage.
The company has converted pipeline momentum into strategic deals: a 55‑SKU global supply agreement with USD90–100 million potential from 2029, GLP‑1 and peptide CDMO contracts, and partnerships for sterile APIs and a liposomal in‑licensed product, indicating meaningful medium/long‑term revenue diversification.
Balance sheet strength is a clear enabler: net cash of approximately INR32,939 million and cash and equivalents of INR35,466 million as of June 30, 2026, which supports aggressive capex plans, R&D investment (INR772 million in Q1) and the ability to pursue additional strategic manufacturing partnerships.
Pharmaceuticals & Biotechnology
Pharmaceuticals
50,738 Cr
Low Risk
45.0
37.0
2.1
4.9
3,171.00
1,575.00
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Nov 05, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Gland Pharma Ltd (GLAND) is currently trading at 3,100.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gland Pharma is an India‑based vertically integrated manufacturer of sterile injectable formulations and a growing CDMO provider, operating multiple finished dosage and API facilities in India and the recently acquired Cenexi network in Europe that together supply the U.S., Europe, Canada, Australia and rest‑of‑world markets. Q1 FY27 highlighted a strong start with consolidated revenue of INR18,003 million (up 20% YoY), CDMO now contributing 50% of revenue, strong U.S. growth of 32% and reported EBITDA margin of 27% (adjusted 28% excluding ESOP), signalling improving profitability driven by higher CDMO mix and operating leverage. The company has converted pipeline momentum into strategic deals: a 55‑SKU global supply agreement with USD90–100 million potential from 2029, GLP‑1 and peptide CDMO contracts, and partnerships for sterile APIs and a liposomal in‑licensed product, indicating meaningful medium/long‑term revenue diversification. Balance sheet strength is a clear enabler: net cash of approximately INR32,939 million and cash and equivalents of INR35,466 million as of June 30, 2026, which supports aggressive capex plans, R&D investment (INR772 million in Q1) and the ability to pursue additional strategic manufacturing partnerships.
Over the past 52 weeks, Gland Pharma Ltd has traded between a low of ₹1,575.00 and a high of ₹3,171.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gland Pharma Ltd has a market capitalization of approximately 50,738.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gland Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 44.95 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 50,738.36 Cr, Gland Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gland Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 44.95. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Fosun’s subsidiary sold 9.897 million shares (98.97 lakh), representing about 6.00% of Gland Pharma’s share capital.
Fosun Pharma said its Singapore unit sold 9.897 million shares (98.97 lakh), representing about 6% of Gland Pharma’s share capital as of September 3, 2026.
Gland Pharma said the deal has annualised revenue potential of USD 90–100 million once all products are commercialised.
Gland Pharma’s 48th AGM is scheduled for Tuesday, August 25, 2026 at 11:00 A.M. IST.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
5125.00 | 60,380 Cr | 27.37 | 4.37 | 1.05 | 16.66 | 18.61 | 10.57 | ||
352.00 | 57,365 Cr | 137.76 | 1.66 | 0.14 | 1.14 | 3.64 | 0.65 | ||
25570.20 | 55,479 Cr | 34.36 | 11.62 | 2.51 | 32.51 | 42.54 | 24.83 | ||
3100.00 | 50,738 Cr | 44.95 | 4.90 | 0.65 | 9.92 | 14.02 | 9.02 | ||
1927.00 | 48,860 Cr | 35.41 | 6.06 | 0.31 | 14.15 | 18.58 | 11.15 | ||
3465.90 | 43,234 Cr | 34.24 | 9.55 | 0.81 | 23.33 | 29.09 | 18.44 | ||
2505.00 | 42,617 Cr | 39.90 | 18.80 | 2.27 | 45.69 | 61.23 | 24.70 | ||
| Median: 7 Co. | — | 3100.00 | 50,738 Cr | 35.41 | 6.06 | 0.81 | 16.66 | 18.61 | 11.15 |
